Study of abemaciclib and diarrhea risk in breast cancer patients
Treatments studied
Part of Cancer, Skin clinical trials.
This trial is for people with hormone receptor-positive breast cancer who are at high risk of recurrence. It looks at how the body processes abemaciclib, a targeted therapy, and whether that affects severe diarrhea, a common side effect.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a woman age 18 or older
- You have luminal A or B breast cancer (hormone receptor-positive, HER2-negative)
- Your breast cancer is stage 2 or 3 and considered high risk for coming back
- You have had surgery to remove the cancer and are starting abemaciclib with hormone therapy
- You have not taken any CDK4/6 inhibitor (like palbociclib, ribociclib, or abemaciclib) before
- You do not have inflammatory bowel disease or other conditions causing chronic diarrhea
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how gut bacteria changes in people taking Abemaciclib (a breast cancer drug) and whether that relates to diarrhea. It may help find ways to prevent or manage this side effect.
This study looks at real-world safety and side effect management of abemaciclib combined with hormone therapy for patients with RH+, HER2- breast cancer. It aims to understand how well patients tolerate treatment outside of clinical trials.
This trial tests whether the drug abemaciclib can help women with hormone receptor-positive, HER2-negative breast cancer who still have signs of cancer DNA in their blood after standard treatment. It aims to prevent a future return of the cancer.
This study tests whether women with early-stage HR+/HER2- breast cancer can safely take a higher dose of the drug abemaciclib (Verzenio) after surgery. The goal is to keep the treatment as strong as possible while managing side effects.
This trial studies how the immune system and other body signals in blood and tumor tissue relate to how well abemaciclib works before breast cancer surgery. The goal is to learn who benefits most from this medicine and why.
This trial tests if adding abemaciclib (a targeted pill) to standard chemotherapy before surgery can shrink HR+/HER2- breast cancer and allow less extensive surgery. It also aims to see if a genetic test (Oncotype DX) can help guide treatment decisions.
Hear when a new Abemaciclib trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.